Eevia Health Plc publishes a new research article comparing Fenoprolic® and Pycnogenol®
Eevia Health Plc ("Eevia" or "The Company") publishes today an article on the comparison of bioactivity profiles between Fenoprolic®, Eevia’s pine bark extract, and Pycnogenol®. The article benchmarks Eevia’s pine bark extract against the market leader for OPC extracts from pine. The study showed that Eevia’s extract performed nearly identically compared to Pycnogenol® across almost 150 biomarkers. Eevia expects the result to move customers and prospects to place new sales orders and -contracts.
Fenoprolic® is Eevia’s flagship product and contains 70% of OPCs (Oligomeric proanthocyanidins). Pycnogenol® has the same concentration of OPC (70%) and is marketed worldwide by Horphag Research in Switzerland for multiple health indications. The market segment for OPC extracts is valued at over EUR 1 billion.
Eevia undertook an extensive study of the bioactivity of Fenoprolic® and is the market leader with the Eurofins BioMAP® Human Primary Cell Phenotypic profiling platform. The Eurofins platform contains over 150 biomarkers across a range of bioactivity systems. Eurofins tested Fenoprolic® and Pycnogenol® in the same way, on the same biomarkers, and on the same human primary cells, which makes the comparison of the bioactivity profile relevant both in quality and magnitude. Eurofins then compared the bioactivity profiles.
Eevia considers the near-identical results remarkable, and Eevia expects that the new information will immediately trigger new sales orders and contracts from customers and prospects.
The research article also promotes this form of bioactivity profiling as a way of showing bioequivalence between products or not, which can also be used to differentiate from imposter products, adulterated ingredients, and products with mostly sugar and flavors but little or no bioactive compounds ("Candyceuticals").
"The BioMAP comparison of our pine bark extract against the market leader is compelling and confirms that our product is nearly identical in vitro bioactivity to the market leader. Substantiating bioactivity in human primary cells can support sales traction and order updates from the marketplace, ” comments Stein Ulve, CEO of Eevia Health Plc.
For further information, please contact:
Stein Ulve, CEO, Eevia Health Plc
Email: stein.ulve@eeviahealth.com or investor@eeviahealth.com
Telephone: +358 400 22 5967
INFORMATION ABOUT EEVIA HEALTH PLC
Eevia Health Plc, founded in March 2017, addresses significant health problems with bioactive compounds extracted from plant materials. The materials are primarily wild harvested from the pristine Finnish and Swedish forests near or above the Arctic Circle. The extracts are sold B2B as ingredients in dietary supplements and food brands globally. These global brands utilize the ingredients in their consumer product formulas.
Eevia Health is a manufacturer of 100% organically certified plant extracts. Although a significant product, Elderberry extract, is made from cultivated berries, most of Eevia’s other raw materials, such as bilberry, lingonberry, chaga-mushroom, and pine bark, are wild-harvested sustainably.
Eevia Health operates a modern green-chemistry production facility in Finland. Manufacturing natural ingredients near the raw material harvest areas, Eevia offers a short value chain with an environmentally friendly carbon footprint, competitive pricing, and extreme transparency. In June 2021, Eevia listed its shares on the Spotlight Stock Market in Sweden under the short name (ticker) EEVIA.
To learn more, please visit www.eeviahealth.com or follow Eevia Health on LinkedIn@EeviaHealth.
